Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other ...

Ohio University researchers have discovered what may be a new way to fight lung cancer that is resistant to other treatments.

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya (R) (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg, a ...

Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other ...

Some women may shed more than men, but this depends on genetics, stress levels, hormonal changes, styling preferences, and health status. Research shows that men are more likely to experience genetic ...

In today’s Pharmaceutical Executive Daily, the FDA approves an expanded indication for Palynziq in patients aged 12 and older ...

After 16 weeks of testing, we noticed visible results. Here are our favorite red light therapy devices for hair growth.

The FDA has approved three new pediatric indications for somapacitan-beco, a once-weekly, long-acting growth hormone ...

Novo Nordisk’s Sogroya is now approved for children aged 2.5 or older with idiopathic short stature, small for gestational age, and Noonan Syndrome.

FDA expands Sogroya approval for pediatric patients with Noonan syndrome, idiopathic short stature, and those born small for gestational age.

Sermorelin.com Unveils Telehealth Peptide Treatment for Lean Mass Preservation Sheridan, United States - February 27, ...

Novo Nordisk received approval from the Food and Drug Administration for three new indications of Sogroya, a growth hormone.